Aripiprazole controlled release - Zysis

Drug Profile

Aripiprazole controlled release - Zysis

Alternative Names: LAO Aripiprazole OW; ZY 102

Latest Information Update: 16 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zysis
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor agonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Bipolar disorders; Schizophrenia

Most Recent Events

  • 16 Feb 2016 Aripiprazole controlled release is still available for partnering (http://www.zysis.com/wp-content/uploads/2015/07/LAO-Aripiprazole-slide-deck.pdf)
  • 13 Nov 2013 Aripiprazole controlled release - Zysis is available for licensing as of 13 Nov 2013. http://www.zysis.com/
  • 13 Nov 2013 Phase-I clinical trials in Bipolar disorders in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top